^
Association details:
| Biomarker: | CD123 positive + FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
62 Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Published date:
11/03/2022
Excerpt:
In this phase 1b/2 study, eligible patients with CD123-positive R/R AML received PVEK+AZA+VEN...Of note, responses were observed in 9 of 11 patients with FLT3-ITD AML with an ORR of 82% and a CCR of 64%.
Secondary therapy:
azacitidine + IMGN632
DOI:
https://doi.org/10.1182/blood-2022-158030
Trial ID:
